Dr. James Kochenderfer and team with the National Cancer Institute at the National Institutes of Health (NIH) are conducting a clinical research study evaluating an investigational immune cell (T-cell) therapy for adults with certain blood cancers that have not responded to standard treatments. The goal is to see if this approach is safe for people with blood cancers.
Who May Be Eligible
Adults (18 years or older) diagnosed with one of the following relapsed or refractory blood cancers may be eligible:
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- T-cell Acute Lymphoblastic Leukemia (T-ALL)
- Chronic Myeloid Leukemia (CML)
- Chronic Myelomonocytic Leukemia (CMML)
- Multiple Myeloma
- Additional eligibility criteria apply, including specific genetic mutations (RAS or TP53) and immune (HLA) markers.
About the Research
This study uses a participant's own immune cells (T cells), which are collected from the blood and modified in a laboratory to recognize and attack specific mutations in cancer cells.
The purpose of this research study is to see if your T cells changed to recognize the mutations in your cancer cells is safe in people with blood cancers.
What Participation May Include
- Screening tests and bone marrow biopsy for genetic testing
- Bone marrow biopsy
- Collection of T cells from the blood
- A short course of chemotherapy to prepare the immune system
- Inpatient Hospitalization; Infusion of modified T cells at the NIH Clinical Center
- Close medical monitoring and follow-up visits
- Participation in this study could potentially span up to 5 years
All study-related activities take place at the NIH Clinical Center in Bethesda, Maryland. Participation is voluntary, and not all individuals will qualify.
For More Information
NIH Clinical Center Office of Patient Recruitment
833-JOIN-NIH
TTY users dial 7-1-1
Email: ccopr@nih.gov
Or go online
Refer to NIH study # 002088-C
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)